Actelion (Actelion) Net Income From Continuing Operations : $723 Mil (TTM As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Actelion's net income from continuing operations for the three months ended in Mar. 2017 was $196 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2017 was $723 Mil.

Actelion Net Income From Continuing Operations Historical Data

The historical data trend for Actelion's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Net Income From Continuing Operations Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Net Income From Continuing Operations

Get a 7-Day Free Trial

329.13

506.60

608.83

550.63

681.61

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Net Income From Continuing Operations	Get a 7-Day Free Trial															181.35	187.60	226.38	112.54	196.34

Actelion Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $723 Mil.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016